Compare TACT & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TACT | PLUR |
|---|---|---|
| Founded | 1996 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.6M | 34.9M |
| IPO Year | 1996 | N/A |
| Metric | TACT | PLUR |
|---|---|---|
| Price | $4.14 | $3.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 54.8K | 44.2K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,258,000.00 | $1,326,000.00 |
| Revenue This Year | $21.67 | $97.38 |
| Revenue Next Year | $7.63 | $293.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 8.27 | ★ 121.74 |
| 52 Week Low | $3.12 | $2.82 |
| 52 Week High | $5.70 | $7.13 |
| Indicator | TACT | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 38.07 | 48.89 |
| Support Level | $4.01 | $2.82 |
| Resistance Level | $4.61 | $3.72 |
| Average True Range (ATR) | 0.16 | 0.33 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 20.93 | 52.73 |
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.